Imagine a future where a universal vaccine for type 1 diabetes (T1D) exists and no one needs to worry about getting T1D.
Why it matters
T1D is a chronic, life-threatening autoimmune disease that is currently not preventable. Eighty-five percent of people who develop it have no family history of the disease, and epidemiologists predict a threefold increase in the number of young people who have T1D by 2050.
At JDRF, we want to change that outlook and make it possible that no one ever again develops T1D. The ultimate aim of our Prevention Program is creating a childhood vaccine to immunize against the causes of T1D. While we work toward that goal, we also are committed to stopping the progression of T1D once it’s begun so we can prevent dependency on insulin therapy.
Our pioneering research
JDRF-funded research has identified a number of potential triggers associated with the onset of T1D, including viruses and environmental conditions. These discoveries could point to ways of developing vaccines that will stop the triggers and prevent autoimmune attacks on the body’s insulin-producing cells.
We’re pursuing a number of promising approaches to prevention, including therapies that prevent or reverse specific gut bacteria changes that have been associated with the development of T1D.
Deciding Whether to Screen for T1D
Screening for type 1 diabetes (T1D) is now available, and is provided through TrialNet, an international network of research centers dedicated to the study, prevention and early treatment of T1D. By screening close relatives of people with T1D, they can monitor the progression of the disease from its earliest stages to the onset of clinical symptoms.Read more
Collaboration to Research Risk Factors in Children
IBM and JDRF announced a new collaboration to develop and apply machine learning methods to analyze years of global type 1 diabetes (T1D) research data and identify factors leading to the onset of T1D in children. This analysis is the first precision medicine effort to identify T1D risk among children.Read more
Intercepting and Preventing the Onset of Type 1 Diabetes
JDRF T1D Fund, a venture philanthropy fund accelerating life-changing solutions to treat, prevent and cure type 1 diabetes (T1D), has invested in Provention’s lead program, which aims to potentially reduce new T1D cases by 50 percent.Read more
Screening a Path to Prevention
Research has shown that type 1 diabetes (T1D) begins well before symptoms appear and progresses to symptomatic disease through distinct, sequential stages. Armed with this knowledge, TrialNet researchers are testing different ways to interrupt disease progression and prevent the onset of symptoms.Read more
New Clues into the Triggers of Type 1 Diabetes
JDRF-supported study findings suggest researchers are narrowing in on factors that may cause type 1 diabetes (T1D). The findings could be an important step toward a key JDRF goal: preventing development of T1D in at-risk individuals.Read more
Could Microbes in the Gut Prevent T1D?
Scientists have identified a connection between microbes in the gut and T1D that could open the door to new prevention strategies.Read more
Making Progress Towards an Oral Vaccine
Oral insulin given to children prompted the kinds of immune responses that may protect against autoimmunity, according to the recent, JDRF-funded “Pre-POINT” study.Read more
Expanding the Definition of T1D
In 2014, JDRF convened experts to redefine the early stages of T1D. The ability to diagnose the disease before onset of clinical symptoms could help prevent progression to insulin therapy.Read more
Expanding Knowledge About an Early Sign of T1D
By studying pancreatic tissue from individuals with T1D, researchers have gained important new insights into the progression of T1D, including insulitis, an early sign of T1D that could yield clues for prevention.Read more
JDRF Forms Partnership to Develop T1D Vaccines
In 2011, JDRF and Selecta Biosciences formed a collaborative research initiative to create vaccines to stop the autoimmune attack that causes T1D.Read more
Meet the experts leading prevention research.
Jessica L. Dunne, Ph.D.
Jessica L. Dunne is director and program lead for JDRF's Prevention Program, which focuses on delaying or preventing the onset of symptomatic T1D.
Jessica L. Dunne, Ph.D.
Sanjoy Dutta, Ph.D.
Sanjoy Dutta is assistant vice president, research, for JDRF, where he focuses on managing and developing ways we can treat T1D.
Sanjoy Dutta, Ph.D.
Explore more life-changing research
Find out why each of these research areas is part of the plan for a world without T1D.